Molecular effects of lithium are partially mimicked by inositol-monophosphatase (IMPA)1 knockout mice in a brain region-dependent manner

European Neuropsychopharmacology

Volumn 25, Issue 3, 2015, Pages 425-434

  Damri, O ^a,b,c,d   Sade, Y ^a,b,c,d   Toker, L ^a,b,c,d   Bersudsky, Y ^b,c,d   Belmaker, R H ^b,c   Agam, G ^a,b,c,d   Azab, A N ^a,c  

^a Department of Clinical Biochemistry and Pharmacology ^*  (Israel)

^b Psychiatry Research Unit   (Israel)

^c BEN GURION UNIVERSITY OF THE NEGEV   (Israel)

^d MENTAL HEALTH CENTER   (Israel)

Author keywords

Cytokines levels; Gene expression; Inositol monophosphatase1; Knockout mice; Lithium

Indexed keywords

INOSITOL DERIVATIVE; INOSITOL MONOPHOSPHATASE 1; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 17; INTERLEUKIN 1BETA; INTERLEUKIN 2; INTERLEUKIN 3; INTERLEUKIN 4; INTERLEUKIN 6; LITHIUM; MARCKS PROTEIN; MESSENGER RNA; MONOCYTE CHEMOTACTIC PROTEIN 1; NEUROPEPTIDE Y; PEROXIREDOXIN 2; PROTEIN BAX; PROTEIN P53; UNCLASSIFIED DRUG; ANTIDEPRESSANT AGENT; CYTOKINE; MEMBRANE PROTEIN; MYO-INOSITOL-1 (OR 4)-MONOPHOSPHATASE; MYRISTOYLATED ALANINE-RICH C KINASE SUBSTRATE; PEROXIREDOXIN; PHOSPHATASE; PROTEIN BCL 2; SIGNAL PEPTIDE;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ARTICLE; BRAIN REGION; CONTROLLED STUDY; DOWN REGULATION; DRUG EFFECT; FRONTAL CORTEX; HIPPOCAMPUS; HYPOTHALAMUS; LITHIUM BLOOD LEVEL; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; ANATOMY AND HISTOLOGY; ANIMAL; BRAIN; DEFICIENCY; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETICS; KNOCKOUT MOUSE; METABOLISM;

ANIMALS; ANTIDEPRESSIVE AGENTS; BCL-2-ASSOCIATED X PROTEIN; BRAIN; CYTOKINES; GENE EXPRESSION REGULATION; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; LITHIUM; MALE; MEMBRANE PROTEINS; MICE; MICE, KNOCKOUT; PEROXIREDOXINS; PHOSPHORIC MONOESTER HYDROLASES; PROTO-ONCOGENE PROTEINS C-BCL-2; RNA, MESSENGER; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84925938744     PISSN: 0924977X     EISSN: 18737862     Source Type: Journal    
DOI: 10.1016/j.euroneuro.2014.06.012     Document Type: Article

References (50)

1. Agam G., Bersudsky Y., Berry G.T., Moechars D., Lavi-Avnon Y., Belmaker R.H. Knockout mice in understanding the mechanism of action of lithium. Biochem. Soc. Trans. 2009, 37:1121-1125.
2. Berridge M.J., Irvine R.F. Inositol phosphates and cell signalling. Nature 1989, 341:197-205.
3. Bersudsky Y., Shaldubina A., Belmaker R.H. Lithium's effect in forced-swim test is blood level dependent but not dependent on weight loss. Behav. Pharmacol. 2007, 18:77-80.
4. Beurel E., Jope R.S. Lipopolysaccharide-induced interleukin-6 production is controlled by glycogen synthase kinase-3 and STAT3 in the brain. J. Neuroinflamm. 2009, 6:9.
5. Boufidou F., Nikolaou C., Alevizos B., Liappas I.A., Christodoulou G.N. Cytokine production in bipolar affective disorder patients under lithium treatment. J. Affect. Disord. 2004, 82:309-313.
6. Cai J.H., Deng S., Kumpf S.W., Lee P.A., Zagouras P., Ryan A., Gallagher D.S. Validation of rat reference genes for improved quantitative gene expression analysis using low density arrays. Biotechniques 2007, 42:503-512.
7. Chen R.W., Chuang D.M. Long term lithium treatment suppresses p53 and Bax expression but increases Bcl-2 expression. A prominent role in neuroprotection against excitotoxicity. J. Biol. Chem. 1999, 274:6039-6042.
8. Chiu C.T., Chuang D.M. Molecular actions and therapeutic potential of lithium in preclinical and clinical studies of CNS disorders. Pharmacol. Ther. 2010, 128:281-304.
9. Cryns K., Shamir A., Van Acker N., Levi I., Daneels G., Goris I., Bouwknecht J.A., Andries L., Kass S., Agam G., Belmaker H., Bersudsky Y., Steckler T., Moechars D. IMPA1 is essential for embryonic development and lithium-like pilocarpine sensitivity. Neuropsychopharmacology 2008, 33:674-684.
10. Cserr H.F., Knopf P.M. Cervical lymphatics, the blood-brain barrier and the immunoreactivity of the brain: a new view. Immunol. Today 1992, 13:507-512.
11. Ebadi M.S., Simmons V.J., Hendrickson M.J., Lacy P.S. Pharmacokinetics of lithium and its regional distribution in rat brain. Eur. J. Pharmacol. 1974, 27:324-329.
12. Goldstein B.I., Kemp D.E., Soczynska J.K., McIntyre R.S. Inflammation and the phenomenology, pathophysiology, comorbidity, and treatment of bipolar disorder: a systematic review of the literature. J. Clin. Psychiatry 2009, 70:1078-1090.
13. Harwood A.J. Lithium and bipolar mood disorder: the inositol-depletion hypothesis revisited. Mol. Psychiatry 2005, 10:117-126.
14. Hashimoto H., Onishi H., Koide S., Kai T., Yamagami S. Plasma neuropeptide Y in patients with major depressive disorder. Neurosci. Lett. 1996, 216:57-60.
15. Heath-Engel H.M., Chang N.C., Shore G.C. The endoplasmic reticulum in apoptosis and autophagy: role of the BCL-2 protein family. Oncogene 2008, 27:6419-6433.
16. Kim H., Lee T.H., Park E.S., Suh J.M., Park S.J., Chung H.K., Kwon O.Y., Kim Y.K., Ro H.K., Shong M. Role of peroxiredoxins in regulating intracellular hydrogen peroxide and hydrogen peroxide-induced apoptosis in thyroid cells. J. Biol. Chem. 2000, 275:18266-18270.
17. Kim Y.K., Myint A.M., Lee B.H., Han C.S., Lee S.W., Leonard B.E., Steinbusch H.W. T-helper types 1, 2, and 3 cytokine interactions in symptomatic manic patients. Psychiatry. Res 2004, 129:267-272.
18. Kim Y.K., Suh I.B., Kim H., Han C.S., Lim C.S., Choi S.H., Licinio J. The plasma levels of interleukin-12 in schizophrenia, major depression, and bipolar mania: effects of psychotropic drugs. Mol. Psychiatry 2002, 7:1107-1114.
19. Klein P.S., Melton D.A. A molecular mechanism for the effect of lithium on development. Proc. Natl. Acad. Sci. USA 1996, 93:8455-8459.
20. Knijff E.M., Breunis M.N., Kupka R.W., de Wit H.J., Ruwhof C., Akkerhuis G.W., Nolen W.A., Drexhage H.A. An imbalance in the production of IL-1beta and IL-6 by monocytes of bipolar patients: restoration by lithium treatment. Bipolar Disord. 2007, 9:743-753.
21. Knijff E.M., Breunis M.N., van Geest M.C., Kupka R.W., Ruwhof C., de Wit H.J., Nolen W.A., Drexhage H.A. A relative resistance of T cells to dexamethasone in bipolar disorder. Bipolar Disord. 2006, 8:740-750.
22. Kuromitsu J., Yokoi A., Kawai T., Nagasu T., Aizawa T., Haga S., Ikeda K. Reduced neuropeptide Y mRNA levels in the frontal cortex of people with schizophrenia and bipolar disorder. Brain Res. Gene Expr. s 2001, 1:17-21.
23. Leboyer M., Soreca I., Scott J., Frye M., Henry C., Tamouza R., Kupfer D.J. Can bipolar disorder be viewed as a multi-system inflammatory disease?. J. Affect. Disord. 2012, 141:1-10.
24. Lenox R.H., Wang L. Molecular basis of lithium action: integration of lithium-responsive signaling and gene expression networks. Mol. Psychiatry 2003, 8:135-144.
25. Li H., Li Q., Du X., Sun Y., Wang X., Kroemer G., Blomgren K., Zhu C. Lithium-mediated long-term neuroprotection in neonatal rat hypoxia-ischemia is associated with antiinflammatory effects and enhanced proliferation and survival of neural stem/progenitor cells. J. Cereb. Blood Flow Metab. 2011, 31:2106-2115.
26. Maes M., Bosmans E., Calabrese J., Smith R., Meltzer H.Y. Interleukin-2 and interleukin-6 in schizophrenia and mania: effects of neuroleptics and mood stabilizers. J. Psychiatr. Res. 1995, 29:141-152.
27. Mathe A.A., Jousisto-Hanson J., Stenfors C., Theodorsson E. Effect of lithium on tachykinins, calcitonin gene-related peptide, and neuropeptide Y in rat brain. J. Neurosci. Res. 1990, 26:233-237.
28. McGeer P.L., McGeer E.G. The inflammatory response system of brain: implications for therapy of Alzheimer and other neurodegenerative diseases. Brain. Res. Brain. Res. Rev. 1995, 21:195-218.
29. Monji A., Kato T., Kanba S. Cytokines and schizophrenia: Microglia hypothesis of schizophrenia. Psychiatry Clin. Neurosci. 2009, 63:257-265.
30. Mukherjee B.P., Bailey P.T., Pradhan S.N. Temporal and regional differences in brain concentrations of lithium in rats. Psychopharmacol. (Berl) 1976, 48:119-121.
31. Parker M.S., Sah R., Balasubramaniam A., Parker S.L. Lithium inhibits internalization and endosomal processing of both neuropeptide Y (NPY) Y1 and transferrin receptors. Neurosci. Lett. 2005, 374:43-46.
32. Pfaffl M.W., Langem I.G., Daxenberger A., Meyer H.H. Tissue-specific expression pattern of estrogen receptors (ER): quantification of ER alpha and ER beta mRNA with real-time RT-PCR. APMIS 2001, 109:345-355.
33. Pineda E., Shin D., Sankar R., Mazarati A.M. Comorbidity between epilepsy and depression: experimental evidence for the involvement of serotonergic, glucocorticoid, and neuroinflammatory mechanisms. Epilepsia 2010, 51(Suppl. 3):110-114.
34. Raison C.L., Capuron L., Miller A.H. Cytokines sing the blues: inflammation and the pathogenesis of depression. Trends Immunol. 2006, 27:24-31.
35. Rao J.S., Harry G.J., Rapoport S.I., Kim H.W. Increased excitotoxicity and neuroinflammatory markers in postmortem frontal cortex from bipolar disorder patients. Mol. Psychiatry 2010, 15:384-392.
36. Rapaport M.H., Guylai L., Whybrow P. Immune parameters in rapid cycling bipolar patients before and after lithium treatment. J. Psychiatr. Res. 1999, 33:335-340.
37. Rapaport M.H., Manji H.K. The effects of lithium on ex vivo cytokine production. Biol. Psychiatry 2001, 50:217-224.
38. Rapoport S.I., Basselin M., Kim H.W., Rao J.S. Bipolar disorder and mechanisms of action of mood stabilizers. Brain Res. Rev. 2009, 61:185-209.
39. Redrobe J.P., Dumont Y., Fournier A., Quirion R. The neuropeptide Y (NPY) Y1 receptor subtype mediates NPY-induced antidepressant-like activity in the mouse forced swimming test. Neuropsychopharmacology 2002, 26:615-624.
40. Redrobe J.P., Dumont Y., Quirion R. Neuropeptide Y (NPY) and depression: from animal studies to the human condition. Life Sci. 2002, 71:2921-2937.
41. Sarkar S., Floto R.A., Berger Z., Imarisio S., Cordenier A., Pasco M., Cook L.J., Rubinsztein D.C. Lithium induces autophagy by inhibiting inositol monophosphatase. J. Cell Biol. 2005, 170:1101-1111.
42. Schiepers O.J., Wichers M.C., Maes M. Cytokines and major depression. Prog. Neuropsychopharmacol. Biol. Psychiatry 2005, 29:201-217.
43. Seelan R.S., Khalyfa A., Lakshmanan J., Casanova M.F., Parthasarathy R.N. Deciphering the lithium transcriptome: microarray profiling of lithium-modulated gene expression in human neuronal cells. Neuroscience 2008, 151:1184-1197.
44. Smith R.S. The macrophage theory of depression. Med. Hypotheses 1991, 35:298-306.
45. Spirtes M.A. Lithium levels in monkey and human brain after chronic, therapeutic, oral dosage. Pharmacol. Biochem. Behav. 1976, 5:143-147.
46. Su K.P., Leu S.J., Yang Y.Y., Shen W.W., Chou Y.M., Tsai S.Y. Reduced production of interferon-gamma but not interleukin-10 in bipolar mania and subsequent remission. J. Affect. Disord. 2002, 71:205-209.
47. Watcharasit P., Bijur G.N., Zmijewski J.W., Song L., Zmijewska A., Chen X., Johnson G.V., Jope R.S. Direct, activating interaction between glycogen synthase kinase-3beta and p53 after DNA damage. Proc. Natl. Acad. Sci. USA 2002, 99:7951-7955.
48. Watkins L.R., Maier S.F., Goehler L.E. Cytokine-to-brain communication: a review & analysis of alternative mechanisms. Life Sci. 1995, 57:1011-1026.
49. Zachrisson O., Mathe A.A., Stenfors C., Lindefors N. Region-specific effects of chronic lithium administration on neuropeptide Y and somatostatin mRNA expression in the rat brain. Neurosci. Lett. 1995, 194:89-92.
50. Zhu Z.F., Wang Q.G., Han B.J., William C.P. Neuroprotective effect and cognitive outcome of chronic lithium on traumatic brain injury in mice. Brain Res. Bull. 2010, 83:272-277.